Literature DB >> 10516045

Amino acid changes at positions 173 and 187 in the human T-cell leukemia virus type 1 surface glycoprotein induce specific neutralizing antibodies.

S Blanchard1, T Astier-Gin, B Tallet, D Moynet, D Londos-Gagliardi, B Guillemain.   

Abstract

The nucleotide sequence of human T-cell leukemia virus type 1 (HTLV-1) is highly conserved, most strains sharing at least 95% sequence identity. This sequence conservation is also found in the viral env gene, which codes for the two envelope glycoproteins that play a major role in the induction of a protective immune response against the virus. However, recent reports have indicated that some variations in env sequences may induce incomplete cross-reactivity between HTLV-1 strains. To identify the amino acid changes that might be involved in the antigenicity of neutralizable epitopes, we constructed expression vectors coding for the envelope glycoproteins of two HTLV-1 isolates (2060 and 2072) which induced human antibodies with different neutralization patterns. The amino acid sequences of the envelope glycoproteins differed at four positions. Vectors coding for chimeric or point-mutated envelope proteins were derived from 2060 and 2072 HTLV-1 env genes. Syncytium formation induced by the wild-type or mutated envelope proteins was inhibited by human sera with different neutralizing specificities. We thus identified two amino acid changes, I173-->V and A187-->T, that play an important role in the antigenicity of neutralizable epitopes located in this region of the surface envelope glycoprotein.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10516045      PMCID: PMC112971     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Neutralizing human monoclonal antibodies to conformational epitopes of human T-cell lymphotropic virus type 1 and 2 gp46.

Authors:  K G Hadlock; J Rowe; S Perkins; P Bradshaw; G Y Song; C Cheng; J Yang; R Gascon; J Halmos; S M Rehman; M S McGrath; S K Foung
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  The ectodomain of the human T-cell leukemia virus type 1 TM glycoprotein is involved in postfusion events.

Authors:  A R Rosenberg; L Delamarre; C Pique; D Pham; M C Dokhélar
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

3.  Neutralizing activity and antibody reactivity toward immunogenic regions of the human T cell leukemia virus type I surface glycoprotein in sera of infected patients with different clinical states.

Authors:  T Astier-Gin; J P Portail; D Londos-Gagliardi; D Moynet; S Blanchard; R Dalibart; J F Pouliquen; M C Georges-Courbot; C Hajjar; S Sainte-Foie; B Guillemain
Journal:  J Infect Dis       Date:  1997-03       Impact factor: 5.226

4.  Immunogenicity of variable regions of the surface envelope glycoprotein of HTLV type I and identification of new major epitopes in the 239-261 region.

Authors:  D Londos-Gagliardi; R Dalibart; S Geoffre; P Dalbon; J F Pouliquen; M C Georges-Courbot; S Sainte-Foie; C Hajjar; A J Georges; J P Moreau; B Guillemain
Journal:  AIDS Res Hum Retroviruses       Date:  1996-07-01       Impact factor: 2.205

5.  Expression and immunogenicity in rats of recombinant adenovirus 5 DNA plasmids and vaccinia virus containing the HTLV-I env gene.

Authors:  M Kazanji; R Bomford; J L Bessereau; T Schulz; G de Thé
Journal:  Int J Cancer       Date:  1997-04-10       Impact factor: 7.396

6.  A novel human T-leukemia virus type 1 cell-to-cell transmission assay permits definition of SU glycoprotein amino acids important for infectivity.

Authors:  L Delamarre; A R Rosenberg; C Pique; D Pham; M C Dokhélar
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

7.  Different HTLV-I neutralization patterns among sera of patients infected with cosmopolitan HTLV-I.

Authors:  S Blanchard; T Astier-Gin; D Moynet; E Edouard; B Guillemain
Journal:  Virology       Date:  1998-05-25       Impact factor: 3.616

8.  Influence of transmembrane domains on the fusogenic abilities of human and murine leukemia retrovirus envelopes.

Authors:  C Denesvre; P Sonigo; A Corbin; H Ellerbrok; M Sitbon
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

9.  Vaccination of rabbits with recombinant vaccinia virus carrying the envelope gene of human T-cell lymphotropic virus type I.

Authors:  E Hakoda; H Machida; Y Tanaka; N Morishita; T Sawada; H Shida; H Hoshino; I Miyoshi
Journal:  Int J Cancer       Date:  1995-02-08       Impact factor: 7.396

10.  A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies.

Authors:  E Baba; M Nakamura; K Ohkuma; J Kira; Y Tanaka; S Nakano; Y Niho
Journal:  J Immunol       Date:  1995-01-01       Impact factor: 5.422

View more
  2 in total

1.  In vivo analysis of replication and immunogenicity of proviral clones of human T-lymphotropic virus type 1 with selective envelope surface-unit mutations.

Authors:  Lee R Silverman; Andrew J Phipps; Andy Montgomery; Soledad Fernandez; Tomonori Tsukahara; Lee Ratner; Michael D Lairmore
Journal:  Blood       Date:  2005-07-26       Impact factor: 22.113

2.  Amino acid variation within the fusion protein of respiratory syncytial virus subtype A and B strains during annual epidemics in South Africa.

Authors:  Elizabeth Agenbach; Caroline T Tiemessen; Marietjie Venter
Journal:  Virus Genes       Date:  2005-03       Impact factor: 2.332

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.